OasisLMS

Section 1 (Advanced Hepatology)
Topic	Faculty
Orientation and Test Taking Strategies	Oren K. Fix, MD, MSc, FAASLD
Portal HTN	Jacqueline (Jackie) G. O'Leary, MD, MPH
Hepatitis A, B, C, D, E Virus Infection:  Pre- and Post-Liver Transplantation	Norah Terrault, MD, MPH, FAASLD
MASLD and Liver Tx Considerations	Mary E. Rinella, M.D.
Alcohol-associated Liver Disease	Jessica L. Mellinger, MD
Metabolic and Genetic Diseases (Adult)	Michael Schilsky, MD, FAASLD
Cholestatic and Autoimmune Liver Diseases	David N. Assis, MD
Nutrition in Patients with Cirrhosis	Jennifer C. Lai, MD, MBA
Liver Disease and the Pregnant Patient	Tatyana Kushner, MD, MSCE
Acute Liver Failure (Adult)	Anne M. Larson, MD, FAASLD
Section 2 (Liver Transplantation)
Transplant Immunology	John M. Vierling, MD, FACP, FAASLD, AGAF
Immunosuppression and Rejection
Selection and Evaluation for Liver Transplantation	Lindsay Y. King, MD
Donor Selection (including Living Donor)	Shimul A. Shah, MD
Medical and Surgical Considerations of Liver Transplantation	Scott W. Biggins, MD, MAS, FAASLD Christopher B. Hughes, MD, FACS
Recurrence of Disease After Liver Transplantation	Robert S. Brown, Jr, MD, MPH, FAASLD
Long Term Complications + Health Maintenance	Risë Stribling, MD
Post Transplant Infections	Nicolas Barros, MD
Section 3 (Miscellaneous)
HCC	Tamar H. Taddei, MD
Liver Neoplasms: Benign and Malignant (Non-HCC)	Julie Heimbach, MD, FAASLD
Vascular Liver Disease	Patrick G. Northup, MD, FAASLD
DILI	Lily Dara, MD
Ethics	Michael L Volk, MD, MSc, FAASLD
Statistics	David Goldberg, MD, MSCE
Pathology Lecture	Maura O'Neil, BS, MD
Section 4 (Pediatrics)
Pediatric Liver Tx 101	Mercedes Martinez, MD Nathaly P. Llore, MD
Biliary Atresia & Cholestasis in Children	Amrita Narang, MD MPH
Pediatric Autoimmune Liver Disease and ALF	James E. Squires MD, MS
Genetic Causes of Ped Liver Disease	Dania Brigham, MD
Pediatric Liver Tumors	Arun Rangaswami, MD

• Review the core concepts as recommended by the ABIM Blueprint for the Transplant Hepatology Board exam
• Diagnose, manage and treat hepatobiliary disorders for the pediatric and adult population
• Review key concepts and management of patients before, during and after liver transplantation

Hepatologists, Gastroenterologists, Surgeons, Physician Assistants, Fellow and Trainees interested in studying and maintaining the ABIM hepatology review board. Others with an interest in liver diseases and transplant are also welcome to participate.

Accreditation and Designation Statement: 

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this other activity for a maximum AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM and ABP Statement:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

      -19.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
      -19.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Release Date: July 1, 2026  Expiration Date: July 1, 2028

COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Presenters: 

David N. Assis, MD:
Research Grant: Gilead

Nicolas Barros, MD
Scientific Consultant/Advisor: Miravista Diagnostics

Scott W. Biggins, MD, MAS, FAASLD:
Research Grant: Salix

Dania Brigham, MD:
Nothing to Disclose

Robert S. Brown, Jr, MD, MPH, FAASLD:
Scientific Consultant/Advisor: Gilead, AbbVie, Intercept Pharmaceuticals, Salix, Mallinkrodt, eGenesis, Madrigal
Research Grants: Gilead, AbbVie, Enanta, Intercept, Mirum

Lily Dara, MD:
Scientific Consultant/Advisor: Intercept Pharmaceuticals
Research Grant: Intercept Pharmaceuticals

Oren K. Fix, MD, MSc, FAASLD:
Nothing to Disclose.

David Goldberg, MD, MSCE: 
Scientific Consultant/Advisor: Pfizer, Inc

Julie Heimbach, MD, FAASLD:
Nothing to Disclose.

Christopher B. Hughes, MD, FACS:
Nothing to Disclose.

Lindsay Y. King, MD:
Nothing to Disclose.

Tatyana Kushner, MD, MSCE:
Scientific Consultant/Advisor: Gilead, HDV, AbbVie, GlaxoSmithKline
Advisory Board: Gilead
Research Grant: Gilead

Jennifer C. Lai, MD, MBA:
Scientific Consultant/Advisor: GenFit, Boehringer/Ingelheim, NovoNordisk
Research Grants: CymaBay, AcellaHealth Inc, Lipocine, Gore Medical Vir Biotechnology

Anne M. Larson, MD, FAASLD:
Royalties/Patents:  UpToDate

Nathaly P. Llore, MD:
Nothing to Disclose.

Jessica L. Mellinger, MD:
Scientific Consultant:  GlaxoSmithKline

Amrita Narang, MD MPH:
Scientific Consultant/Advisor: Mirum
Speakers Bureau: Ipsen

Patrick G. Northup, MD, FAASLD:
Nothing to Disclose.

Jacqueline G. O'Leary, MD, MPH:
Scientific Consultant/Advisor: Genfit, Grifols, AbbVie, Gilead, Mallinckrodt, Astellas, NovoNordisk, Cellion, Pharmaln

Maura O'Neil, BS, MD
Nothing to Disclose.

Mary E. Rinella, MD:
Scientific Consultant/Advisor: Boehringer Ingelheim, Intercept Pharmaceuticals, GlaxoSmithKline, Eli Lilly & Co., Inc., Madrigal, NovoNordisk, Cytodyn, HistoIndex, Sonic Incytes, Takeda Pharmaceuticals

Michael Schilsky, MD, FAASLD:
Scientific Consultant: Depymed, Arbormed, Biovie, Salix

Shimul A. Shah, MD: 
Scientific Consultant: Veloxis
Research Grants: Organ Recovery Systems, CareDx, AstraZeneca

Ashina Singh, MD:
Nothing to Disclose

Rise Stribling, MD:
Nothing to Disclose.

Tamar H. Taddei, MD:
Nothing to Disclose.

Norah Terrault, MD, MPH, FAASLD:
Data Safety Monitoring Board: Moderna (ended July 2022)
Scientific Consultant/Advisor: CCO Hepatitis, CLDF, Gilead Sciences (ended in 2022)

John M. Vierling, MD, FACP, FAASLD, AGAF:
Employee: Athenex, Inc.
Scientific Consultant/Advisor: AbbVie, Alexion, Arena, Blade, BristolMyers Squibb, CymaBay, Gilead, Durect, First Thoughts, Fractal, Ipsen, Kezar, LabCorp, Eli Lilly & Co., Inc., Madrigal, Mallinckrodt, Merck & Co., Inc, Moderna, New Horizons, Novartis, Ocalot Bio, SciGen, Takeda, Umecrine, HepQuant, UpToDate
Research Grant: AbbVie, Allergan, Alnlaym, Arena, Arrowhead, 89Bio, Blade, Celgene, Bristol Myers-Squibb, Conatus, CymaBay, Eiger, Eisai, Enanta, Escient, Evive, Galectant, Pfizer, Inc, Pliant, Protagonist, Sagamet, Sundise, Taiwan J, Tobira, Zydus

Michael Volk, MD, MSc, FAASLD:
Scientific Consultant/Advisor: BioVie, Inc.
Speakers Bureau: Salix

2024 Planning Committee:

Amy Taylor, MD
Nothing to Disclose

Ayman Koteish, MD, FAASLD
Nothing to Disclose

Kamron Pourmand, MD
Nothing to Disclose

Alexander Kuo, MD, FAASLD
Nothing to Disclose

Mitchell Mah’Moud, MD, FACG, AGAF, FAASLD
Nothing to Disclose

Heather Patton, MD, FAASLD
Nothing to Disclose

Dekey Llewa, MD
Nothing to Disclose

Ryan Taylor, MD, FAASLD
Nothing to Disclose

Reviewers and Staff:

Ayman Koteish, MD, FAASLD
Nothing to Disclose

Brian Kim, MD, FAASLD
Nothing to Disclose

James F. Crismale, MD
Nothing to Disclose

Pratima Sharma, MD, MS
Leadership in a Related Board: Liver Transplantation

Rolland C. Dickson, MD, FAASLD
Nothing to Disclose

Laura Shelters, MS Ed.
Nothing to Disclose

Kelly Marks
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose

Please review the AASLD Privacy Policy before starting this course.